Mytos, a UK-based cell therapy manufacturing company, has inaugurated its first automated contract development and manufacturing organization (CDMO) facility located within the Cell and Gene Therapy Catapult's Stevenage Innovation Centre. The site employs Mytos' iDEM automation technology aiming to address regenerative medicine bottlenecks by enabling scalable, cost-effective manufacturing of stem cell-derived therapies. The facility targets clinical production readiness by September 2026 with potential capacity for thousands of autologous and allogeneic doses annually.